News Releases
Phase 3 DECISION Trial of Nexavar (sorafenib) Meets Primary Endpoint
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
AstraZeneca announces trade name Caprelsa for vandetanib
AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Caprelsa for the recently approved orphan drug vandetanib, a treatment for medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.